Researchers have identified hematopoietic stem and progenitor cells (HSPCs) that are liberated from bone marrow niches by a myocardial infarction (MI). These progenitor cells migrate from the bone marrow and seed the spleen. From there they provide a sustained boost in monocyte production that can contribute to artherogenesis. These cells and the process behind their release represent a novel therapeutic opportunity for survivors of MI.
You Might Also Like
Also By This Author
“We have a good explanation why reinfarction is frequent: MI accelerates atherosclerosis,” explains Matthias Nahrendorf, MD, PhD. Dr. Nahrendorf is assistant professor at Harvard Medical School, Boston, and one of the corresponding authors of a related study published in Nature.1
MI and stroke are triggered by the destabilization and rupture of lipid-rich plaques in the arterial wall. Patients who survive acute coronary syndromes go on to have a higher risk for recurrent events. The biological connection between the first event and recurrent events was previously unknown. Dr. Nahrendorf and colleagues demonstrate that acute MI or stroke increases arthrosclerosis as well as inflammation in distal atherosclerotic plaques.
The study utilized Apoe-/- mice that develop spontaneous atherosclerotic lesions. The researchers imaged protease activity in these mice and used the activity as a marker of plaque lesion vulnerability. They found that after MI or stroke, Apoe-/- mice developed larger atherosclerotic lesions that persisted over many weeks and contained a large number of monocytes. They then searched for the source of the surplus monocytes in the plaques.
When they measured monocyte progenitor content in mice after MI, they found an increase in the spleen. When mice were splenectomized at the time of MI, there was no acceleration in atherosclerosis.
A Puzzling Finding
The researchers were puzzled, however, because granulocyte macrophage progenitors and macrophage dendritic cell progenitors have only a limited capacity for self-renewal. This limitation was not consistent with the large numbers of monocytes that were exiting the spleen and entering the plaques. Upon further investigation, they discovered that the monocyte progenitor cells did not originate in the spleen, but rather resulted from a burst in inflammatory cells in the bone marrow.
As Dr. Nahrendorf explains, “Atherosclerosis is an inflammatory disease starting in the bone marrow. This, in addition to the spleen, is where macrophages are made.”
It appears that the sympathetic nervous system liberates the hematopoietic cells from their niches by signaling through the β3-adrenoceptor. Indeed, treatment with a β3-adrenoceptor blocker in wild-type mice reduced splenic accumulation of progenitors after MI. Treatment of Apoe-/-mice with a β3-blocker lowered protease activity, myeloid cell count, and mRNA levels of inflammatory cytokines in the plaque.